Global News and Digital Insights
for the Healthcare Industry

Sarepta Therapeutics seeks FDA’s pathway approval for gene therapy

Sarepta Therapeutics is one of the firms working on gene therapy and has enough evidence on hand for the potential treatment of Duchenne muscular dystrophy. The firm claims that it has enough clinical data that shows their treatment is safe and effective to treat muscle-wasting disorder. Though an important Phase 3 trial is still underway and may yield data the coming year, the firm is interacting with regulators for submission under approval pathways.

Read More from MedcityNews

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn